News Image

Exploring NYSE:PFE's dividend characteristics.

By Mill Chart

Last update: Sep 25, 2023

Discover PFIZER INC (NYSE:PFE)—a stock that our stock screener has recognized as a solid dividend pick with strong fundamentals. NYSE:PFE showcases decent financial health and profitability while providing a sustainable dividend. We'll explore the specifics further.

Assessing Dividend for NYSE:PFE

ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:PFE scores a 8 out of 10:

  • With a Yearly Dividend Yield of 4.99%, PFE is a good candidate for dividend investing.
  • PFE's Dividend Yield is rather good when compared to the industry average which is at 3.87. PFE pays more dividend than 97.62% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 2.64, PFE pays a better dividend.
  • PFE has paid a dividend for at least 10 years, which is a reliable track record.
  • PFE has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

How do we evaluate the Health for NYSE:PFE?

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has achieved a 5 out of 10:

  • The Altman-Z score of PFE (2.66) is better than 72.86% of its industry peers.
  • PFE's Debt to FCF ratio of 6.13 is amongst the best of the industry. PFE outperforms 84.76% of its industry peers.
  • A Current Ratio of 2.12 indicates that PFE has no problem at all paying its short term obligations.

Profitability Examination for NYSE:PFE

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:PFE, the assigned 8 is noteworthy for profitability:

  • Looking at the Return On Assets, with a value of 9.75%, PFE belongs to the top of the industry, outperforming 90.95% of the companies in the same industry.
  • The Return On Equity of PFE (21.68%) is better than 91.90% of its industry peers.
  • With an excellent Return On Invested Capital value of 11.96%, PFE belongs to the best of the industry, outperforming 90.00% of the companies in the same industry.
  • The 3 year average ROIC (16.16%) for PFE is well above the current ROIC(11.96%). The reason for the recent decline needs to be investigated.
  • The Profit Margin of PFE (27.55%) is better than 94.76% of its industry peers.
  • Looking at the Operating Margin, with a value of 31.21%, PFE belongs to the top of the industry, outperforming 95.71% of the companies in the same industry.
  • PFE's Operating Margin has improved in the last couple of years.
  • With a decent Gross Margin value of 68.78%, PFE is doing good in the industry, outperforming 73.81% of the companies in the same industry.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Our latest full fundamental report of PFE contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

PFIZER INC

NYSE:PFE (4/26/2024, 7:09:35 PM)

After market: 25.45 +0.05 (+0.2%)

25.4

+0.14 (+0.55%)

PFE News

News Image5 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

News Image13 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Image17 hours ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

You'll get dividends and more with these great stocks.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

News Image2 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
News Image3 days ago - The Motley FoolWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

News Image3 days ago - BloombergPfizer’s First Gene Therapy Gets Approval for Clotting Disorder

Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.

News Image3 days ago - CNBCFDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. 

News Image3 days ago - Investor's Business DailyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy

Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

News Image3 days ago - Pfizer Inc.U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
PFE Links
Follow us for more